In The News
Katy Perry wins appeal in trade mark fight with Aussie designer
NSW lawyers told AI cannot be used to generate affidavits, witness statements
Group members get nothing in RoundUp class action settlement
Second judge has rosier view of claims in class action over $85M development
Law firm report clears WiseTech founder Richard White of misconduct
Union boss says she faces charges over alleged $2.7M scheme, wants FWC case stayed
Pharmacor says AstraZeneca’s Brilinta patent should not have been extended
Clyde & Co sued by insurers over indemnity advice
Russells partner accused of bullying told lawyer she was ‘very negative’
‘Our integrations are on track’: Class action flags WiseTech response to short seller report
Please login to bookmarkClose

Mesoblast has agreed to settle a shareholder class action centred on statements to the market about its Remestemcel-L treatment, resolving claims it misrepresented the efficacy of the therapy for COVID-19 patients.

Subscribe to Lawyerly to access this article.

Already a subscriber?
Lost your password?
error: The content is secured.

For information on rights and reprints, contact subscriptions@lawyerly.com.au